Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?The Motley Fool • 03/10/24
The FDA approved Wegovy for reducing heart attack and stroke risk in overweight patientsFast Company • 03/08/24
Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular RiskInvestors Business Daily • 03/08/24
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverageCNBC • 03/08/24
Novo Nordisk CEO says innovation in obesity may justify higher price in some segmentsReuters • 03/08/24
Novo Nordisk shares overhyped? One investment bank certainly thinks they are overvaluedProactive Investors • 03/08/24
Ozempic Maker's New Weight Loss Pill Beats Wegovy In Early Trial — What To Know About Novo Nordisk's AmycretinForbes • 03/07/24